The Effects of Ramipril in Individuals at Risk for Alzheimer's Disease: Results of a Pilot Clinical Trial
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Research shows that certain antihypertensives taken during midlife confer Alzheimer's disease (AD) related benefits in later life. We conducted a clinical trial to evaluate the extent to which the angiotensin converting enzyme inhibitor (ACE-I), ramipril, affects AD biomarkers including cerebrospinal fluid (CSF) amyloid-β (Aβ) levels and ACE activity, arterial function, and cognition in participants with a parental history of AD. This four month randomized, double-blind, placebo-controlled, pilot clinical trial evaluated the effects of ramipril, a blood-brain-barrier crossing ACE-I, in cognitively healthy individuals with mild, or Stage I hypertension. Fourteen participants were stratified by gender and apolipoprotein E ε4 (APOE ε4) status and randomized to receive 5 mg of ramipril or matching placebo daily. Participants were assessed at baseline and month 4 on measures of CSF Aβ(1-42) and ACE activity, arterial function, and cognition. Participants were middle-aged (mean 54 y) and highly educated (mean 15.4 y), and included 50% men and 50% APOE ε4 carriers. While results did not show a treatment effect on CSF Aβ(1-42) (p = 0.836), data revealed that ramipril can inhibit CSF ACE activity (p = 0.009) and improve blood pressure, however, there were no differences between groups in arterial function or cognition. In this study, ramipril therapy inhibited CSF ACE activity and improved blood pressure, but did not influence CSF Aβ1-42. While larger trials are needed to confirm our CSF Aβ results, it is possible that prior research reporting benefits of ACE-I during midlife may be attributed to alternative mechanisms including improvements in cerebral blood flow or the prevention of angiotensin II-mediated inhibition of acetylcholine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mental Rotations, a Group Test of Three-Dimensional Spatial Visualization
Vandenberg, S. G., & Kuse, A. R. (1978) · Perceptual and Motor Skills · doi:10.2466/pms.1978.47.2.599 · Cited by 2,620
(2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1069 · Cited by 988
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898
KARAMANOGLU, M., O'ROURKE, M. F., AVOLIO, A. P., & KELLY, R. P. (1993) · European Heart Journal · doi:10.1093/eurheartj/14.2.160 · Cited by 873 · cited 1×
“Central aortic pressures were derived from radial tonometry using a generalized, validated, transfer function [29, 30].”
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
Li, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486
Dufouil, C., Chalmers, J., Coskun, O., Besançon, V., Bousser, M.-G., Guillon, P., MacMahon, S., Mazoyer, B., Neal, B., Woodward, M., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.501163 · Cited by 461
Jacobs, H. I. L., Van Boxtel, M. P. J., Jolles, J., Verhey, F. R. J., & Uylings, H. B. M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.06.009 · Cited by 293
Aβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
Antihypertensive drugs and incidence of dementia: the Rotterdam Study
in’t Veld, B. A., Ruitenberg, A., Hofman, A., Stricker, B. H. C., & Breteler, M. M. B. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00241-4 · Cited by 254 · cited 1×
“…of clinical trials report a beneficial effect of antihypertensives on AD incidence, disease however, not all studies support these associations [8–11] Discrepant findings are likely attributed to methodological inconsistencies such dementia type severity, length of the study, concomitant…”
Davies, N. M., Kehoe, P. G., Ben-Shlomo, Y., & Martin, R. M. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110347 · Cited by 212 · cited 1×
“Recent studies show that ADrelated cognitive benefits attributed to antihypertensive therapy is most promising in patients taking angiotensin II receptor blockers (A2RB) or angiotensin converting enzyme inhibitors (ACE-I [15, 16]; For a comprehensive review see [17]).”
Eckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196
Rozzini, L., Chilovi, B. V., Bertoletti, E., Conti, M., Rio, I. D., Trabucchi, M., & Padovani, A. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1523 · Cited by 93 · cited 1×
“Some antihypertensive medications have been shown to decrease the incidence of AD and progression of cognitive decline among AD patients [11–14].”
A Multi-Center Study of ACE and the Risk of Late-Onset Alzheimer's Disease
Belbin, O., Brown, K., Shi, H., Medway, C., Abraham, R., Passmore, P., Mann, D., Smith, A. D., Holmes, C., McGuinness, B., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101914 · Cited by 34 · cited 1×
“Increasing research reporting the contribution of hypertension to Alzheimer’s disease (AD) has led investigators to explore the use of antihypertensive medications as a potential therapy for persons with AD [1–7].”
Effect of enalapril maleate on cerebral blood flow in patients with chronic heart failure.
Kamishirado, H., Inoue, T., Fujito, T., Kase, M., Shimizu, M., Sakai, Y., Takayanagi, K., Morooka, S., Natsui, S., & Kamishirado, H. (1997) · Angiology · doi:10.1177/000331979704800806 · Cited by 27
Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study
Khachaturian, A. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.noc60013 · Cited by 3
Cited by
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
“As an antihypertensive medication, ramipril is a specific angiotensin-converting enzyme inhibitor; however, ramipril was tested and failed in a pilot clinical trial.(229) Therefore, trial failures of treatments related to the neurovascular hypothesis and related hypotheses suggest that these hypotheses alone may not b…”
BackgroundDefining the relationship between hypertension, cognitive decline, and dementia: a review
Walker, K. A., Power, M. C., & Gottesman, R. F. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0724-3 · Cited by 394
Drug repositioning and repurposing for Alzheimer disease
Ballard, C., Aarsland, D., Cummings, J., O’Brien, J., Mills, R., Molinuevo, J. L., Fladby, T., Williams, G., Doherty, P., Corbett, A., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0397-4 · Cited by 201
The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease
Jochemsen, H. M., Teunissen, C. E., Ashby, E. L., van der Flier, W. M., Jones, R. E., Geerlings, M. I., Scheltens, P., Kehoe, P. G., & Muller, M. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt257 · Cited by 77
A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64
Metadata
- Authors
- Wharton, W., Stein, J. H., Korcarz, C., Sachs, J., Olson, S. R., Zetterberg, H., Dowling, M., Ye, S., Gleason, C. E., Underbakke, G., Jacobson, L. E., Johnson, S. C., Sager, M. A., Asthana, S., & Carlsson, C. M.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2012-09-25
- Volume
- 32
- Issue
- 1
- Pages
- 147-156
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1835154286
- Cited by
- 70
- References
- 17
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.